Lapatinib

CAS: 231277-92-2

Ref. TR-L175808

Produktinformation

• Name: Lapatinib
• Synonyme: 4-Quinazolinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]-, N-[3-Chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]-4-quinazolinamine, 4-[[3-Chloro-4-(3-fluorobenzyloxy)phenyl]amino]-6-[5-[[(2-methanesulfonylethyl)amino]methyl]furan-2-yl]quinazoline, GSK 572016, GW 572016, GW 572016X, N-[3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl]-6-[5-[[[2-(methanesulfonyl)ethyl]amino]methyl]-2-furyl]-4-quinazolinamine, N-[3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl]-6-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furyl]-4-quinazolinamine, N-[3-Chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]furan-2-yl]quinazolin-4-amine, N-[4-(3-Fluorobenzyloxy)-3-chlorophenyl]-6-[5-[[2-(methylsulfonyl)ethylamino]methyl]furan-2-yl]quinazolin-4-amine
• Marke: TRC
• Beschreibung: Applications Lapatinib is a selective inhibitor of epidermal growth factor receptor (EGFR) and HER-2 tyrosine kinases. This drug is used to treat breast cancer, especially metastatic breast cancer that has progressed after trastuzumab treatment and other chemotherapy.References Konecny, G., et al.: Cancer Res., 66, 1630 (2006); Geyer, C., et al.: N. Engl. J. Med., 355, 2733 (2006)

Chemische Eigenschaften

• Molekulargewicht: 581.06
• Formel: C₂₉H₂₆ClFN₄O₄S
• Farbe/Form: Light Yellow
• InChl: InChI=1S/C29H26ClFN4O4S/c1-40(36,37)12-11-32-16-23-7-10-27(39-23)20-5-8-26-24(14-20)29(34-18-33-26)35-22-6-9-28(25(30)15-22)38-17-19-3-2-4-21(31)13-19/h2-10,13-15,18,32H,11-12,16-17H2,1H3,(H,33,34,35)